Loading...
Market
Story
Eli Lilly's Zepbound Shows 38% Reduction in Heart Failure Risk in Obesity-Related Phase 3 Trial with 700 Participants
Aug 1, 2024, 11:00 AM
Eli Lilly's weight-loss drug Zepbound has shown significant cardiovascular benefits in a recent late-stage study. The SUMMIT phase 3 trial, which involved over 700 participants, demonstrated that tirzepatide, the active ingredient in Zepbound, reduced the risk of heart failure outcomes by 38% compared to a placebo. The study also highlighted improvements in heart failure symptoms and physical limitations among patients with obesity-related heart failure and preserved ejection fraction. These findings mark the first trial to establish the long-term cardiovascular benefits of Zepbound, potentially positioning it as a leading treatment for patients with heart failure and obesity.
View original story
Similar markets
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Less than 500,000 units • 25%
500,000 to 1 million units • 25%
1 million to 2 million units • 25%
More than 2 million units • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
1st • 25%
2nd • 25%
3rd • 25%
4th or lower • 25%
0 new partnerships • 25%
1-2 new partnerships • 25%
3-4 new partnerships • 25%
5 or more new partnerships • 25%
Below $45 billion • 25%
$45 billion to $45.5 billion • 25%
$45.5 billion to $46 billion • 25%
Above $46 billion • 25%
$45.4 billion to $46.6 billion • 25%
Less than $45.4 billion • 25%
More than $46.6 billion • 25%
Between $46.0 billion and $46.6 billion • 25%